glp-1 drug manufacturers Receptor Agonist Companies and Competitive Landscape Compound versions of GLP-1 drugs
Description
The switch from tirzepatide to semaglutide is the most common transition and is generally well tolerated
How It Works Mimics the GLP-1 hormone to reduce appetite and increase satiety Slows gastric emptying food moves through the stomach more slowly, keeping you feeling full longer Acts on receptors in the hypothalamus to reduce hunger signaling in the brain Supports blood sugar regulation by stimulating insulin release when glucose is present Clinical Results In clinical trials, participants using Semaglutide alongside lifestyle modifications lost an average of 15% of their body weight over 68 weeks
Author Contributions Conceptualization, V.K
If some patients are using food as a form of comfort or reward regulation, could the satiety and central effects of GLP-1 agonists reduce the drive toward other reward-seeking behaviours as well
doi: 10.1111/dme.15248
With saxagliptin, only events adjudicated as definite and possible pancreatitis were available from the final SAVOR-TIMI 53 manuscript
